Company news

Cardiff Oncology, Inc. news in 2020

Cardiff Oncology, Inc.'s news releases, calls and decks from 2020, newest first.

View company

Cardiff Oncology Announces the Appointment of Dr. Rodney Markin as Chairman of the Board

December 20, 2020

Cardiff Oncology Announces Third Quarter 2020 Results and Highlights

November 4, 2020

Cardiff Oncology Prices Public Offering

September 28, 2020

Cardiff Oncology Announces Proposed Public Offering

September 28, 2020

Cardiff Oncology Announces Second Quarter 2020 Results and Highlights

August 10, 2020

Cardiff Oncology Data Continues to Demonstrate Efficacy, Durability and Safety of Onvansertib in Patients with Difficult-to-Treat Relapsed/Refractory AML

June 14, 2020

Cardiff Oncology Announces Expanded Access Program for Onvansertib in KRAS-Mutated Metastatic Colorectal Cancer as Follow-On to Fast Track Designation

June 8, 2020

Cardiff Oncology Announces Fast Track Designation Granted by the FDA to Onvansertib for Second-Line Treatment of KRAS-Mutated Colorectal Cancer

May 27, 2020

Cardiff Oncology Announces $2.5 Million Equity Investment by Biotech-Focused Fundamental Investor Acorn Bioventures

May 26, 2020

Cardiff Oncology Announces Private Placement Investment by Board of Directors and Chief Executive Officer

May 18, 2020

Trovagene Announces Changing of Company Name to Cardiff Oncology and Appointment of Mark Erlander, PhD, as Chief Executive Officer

May 5, 2020

Decks in 2020